La Merie

A biogeneric company leads the field of next generation human growth hormone (hGH)

BARCELONA, Spain | April 24, 2005 | The global hGH market of US$ 2.2 bln in 2004 is not endangered by the only three biogeneric competitors in regulated countries, but by next generation developments of more convenient administration regimens and forms. Following Genentech’s enforced market withdrawal of its Nutropin Depot preparation; the field now is lead by Korea-based LG Life Science and its European co-development partner BioPartners with the slow release formulation of hGH (LB03002) which received regulatory clearance in the US and in Europe to initiate phase III studies. Current market leaders Pfizer (33 % market share), Eli Lilly (19.4 %), Novo Nordisk (16.8 %), Genentech (16 %) and Serono (12.1 %) only have early stage R&D projects with next generation formulations. These results were found in a search conducted by La Merie Business Intelligence. The results were published in the October 24 issue of R&D Pipeline News, edited by La Merie.

The first biogeneric hGH preparation (Omnitrope) from Sandoz (Novartis) is cleared for sale in Australia and received positive opinions from European and US regulators, but marketing clearance so far was not granted, although basic hGH patents already expired. BioPartners submitted the marketing application for the yeast produced hGH already in the fourth quarter of 2004 to the EMEA. Canadian Cangene and partners Apotex and BioGeneriX are still in phase III trials.

All first generation and biogeneric hGH preparations so far require daily parenteral administration which is inconvenient for the patient. Less frequent administration and pain-avoiding needle-free delivery systems would constitute a real advantage. Ongoing R&D projects concentrate on slow-release and long-acting hGH molecules as well as on oral and pulmonary delivery systems. Transdermal and intranasal systems are also offered by the drug delivery industry, whereas low cost production in transgenic cows or aquatic plants still is in its infancy. The number of hGH manufacturing companies in countries without patent protection and, therefore, potential biogeneric producers, is small despite a continuosly growing market due to life cycle management measures and label extensions.

About La Merie
La Merie S.L. is a Business Intelligence enterprise fully dedicated to provide high quality R&D information to the biopharmaceutical industry. La Merie offers individual consultancy services and publishes reports and periodicals. For more information visit www.lamerie.com .

About PipelineReview.com
PipelineReview.com is the News Center and Online Store of La Merie Business Intelligence focused on R&D in the Biopharmaceutical Industry. Visitors of PipelineReview.com will find R&D relevant press releases and can receive selected R&D news from one or more of the site’s News Channels. For more information visit www.pipelinereview.com.

SOURCE: La Merie Business Intelligence

[ top of the page ]